List of Publicly Traded Small-Cap Biotech Companies Listed on Major U.S. Exchanges

This list includes small-sized biotech companies with market capitalizations between 300 million and two billion dollars. We update this page at the start of every month so it is possible that a company’s market cap might fall below 300 million or go above two billion between updates. In parentheses you will find a short description or areas of focus for the company. Additional biotech companies can be found in the following sections:

List of Biotech Companies

Large-Cap Biotech Stocks

Mid-Cap Biotech Stocks

Micro-Cap Biotech Stocks

Nano-Cap Biotech Stocks

Molecular Diagnostics

In parentheses you will find a short description or areas of focus for the company. A comparison widget that shows trend, earnings per share (EPS), P/E ratio and beta for each of the companies on this list can be accessed through the link below.

Small-Cap Biotech Industry Comparison Widget

Select the company’s link to access charts, news links and company website and social media information.

Biotech: Small-Cap Stocks

AC Immune SA (ACIU) (IPO September 23: biopharmaceutical company focused on diseases that are associated with protein misfolding)

Anika Therapeutics Inc. (ANIK) (Therapeutic products for tissue protection, healing and repair; animal health, ophthalmic, joint health and orthopedic products, surgical products to treat ENT disorders, wound care products)

BioSpecifics Technologies Corp (BSTC) (Biopharmaceutical company: injectable collagenase used for treatment of Dupuytren’s contracture and Peyronie’s disease)

Editas Medicine, Inc. (EDIT) (IPO February 3, 2016: Genome editing company)

Emergent Biosolutions, Inc. (EBS) (Biopharmaceutical company: therapeutics and vaccines in hematology/oncology; transplantation and infectious disease; biological defense products)

FibroGen, Inc. (FGEN) (Biopharmaceutical company: anemia in chronic kidney disease, liver fibrosis, pancreatic cancer, corneal blindness)

Five Prime Therapeutics, Inc. (FPRX) (Protein therapeutics)

Inovio Pharmaceuticals, Inc. (INO) (Cancer, infectious diseases, vaccines)

La Jolla Pharmaceutical Company (LJPC) (Biopharmaceutical company: therapies for patients suffering from life-threatening diseases)

Nektar Therapeutics (NKTR) (Biopharmaceutical company: anti-infective, anti-viral, immunology, oncology, pain)

Progenics Pharmaceuticals Inc. (PGNX) (Oncology company: diagnostic and therapeutic needs of prostate cancer patients)

PTC Therapeutics, Inc. (PTCT) (Biopharmaceutical company: oral treatments)

Sucampo Pharmaceuticals, Inc. (SCMP) (Biopharmaceutical company: drug approved for the treatment of CIC in adults and OIC in adults with chronic, non-cancer pain)

Theravance Biopharma, Inc. (TBPH) (Biopharmaceutical company: diseases of the lung, gastrointestinal tract, infectious diseases)

Wave Life Sciences Ltd. (WVE) (IPO in November 2015: Biopharmaceutical company; stereopure nucleic acid therapeutic candidates)


Revance Therapeutics, Inc. (RVNC) (Biopharmaceutical company: botulinum toxin products used in aesthetic and therapeutic applications)


Aimmune Therapeutics, Inc. (AIMT) (IPO in August 2015: Biopharmaceutical company: allergies)

DBV Technologies S.A. (DBVT) (France: therapies for food and pediatric allergy patient)


Achaogen, Inc. (AKAO) (Biopharmaceutical company: antibacterials to treat multi-drug resistant gram-negative infections)


Immunomedics, Inc. (IMMU) (Biopharmaceutical company: antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases)

PDL BioPharma, Inc. (PDLI) (Patents and royalty assets: antibody humanization patents)

Prothena Corporation plc (PRTA) (Ireland: therapeutic monoclonal antibodies directed specifically to disease-causing proteins)

Xencor, Inc. (XNCR) (Antibody therapeutics: autoimmune disorders, asthma and allergic diseases, cancer)


Organovo Holdings, Inc. (ONVO) (3D bioprinting technology)


Coherus BioSciences, Inc. (CHRS) (Biosimilar pure play)


Cerus Corporation (CERS) (Biomedical products company: blood safety)

Global Blood Therapeutics Inc. (GBT) (Therapeutics for patients with grievous blood-based disorders)

Portola Pharmaceuticals, Inc. (PTLA) (Biopharmaceutical company: thrombosis and hematological diseases)


Adaptimmune Therapeutics plc (ADAP) (IPO in May 2015, United Kingdom, biopharmaceutical company: cancer immunotherapy products)

Aduro BioTech, Inc. (ADRO) (IPO in April 2015: Cancer immunotherapy; pancreatic cancer)

Advaxis, Inc. (ADXS) (Clinical-stage biotechnology company: immunotherapies to treat cancer)

Agios Pharmaceuticals, Inc. (AGIO) (Biopharmaceutical company: cancer and rare genetic disorders of metabolism)

Array BioPharma Inc. (ARRY) (Biopharmaceutical company: targeted small molecule drugs used to treat patients afflicted with cancer)

Atara Biotherapeutics, Inc. (ATRA) (Molecularly-targeted product candidates and T-cell product candidates; cancer, kidney disease and other illnesses)

Beigene, Ltd. (BGNE) (IPO February 3, 2016: Biopharmaceutical company with therapeutics designed to treat cancer)

Bellicum Pharmaceuticals, Inc. (BLCM) (Biopharmaceutical company: cellular immunotherapies for various forms of cancer; hematological and solid tumors, orphan inherited blood disorders)

Blueprint Medicines Corporation (BPMC) (IPO in April 2015: Biopharmaceutical company: kinase inhibitors for genomically defined cancers)

Cellectis SA (CLLS) (IPO in March 2015, France: Gene-editing company; cancer therapies based on engineered T cells)

Celldex Therapeutics, Inc. (CLDX) (Therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines; brain cancer, triple negative breast cancer)

ChemoCentryx, Inc. (CCXI) (Biopharmaceutical company: orally-administered therapeutics for the treatment of autoimmune diseases, inflammatory disorders and cancer)

Clovis Oncology, Inc. (CLVS) (Biopharmaceutical company: cancer treatments; non-small cell lung cancer, ovarian cancer, pancreatic cancer, breast and lung cancers)

Corvus Pharmaceuticals, Inc. (CRVS) (IPO March 23, 2016: Biopharmaceutical company focused on immuno-oncology therapies for cancer)

Curis, Inc. (CRIS) (Drug candidates for the treatment of human cancers)

CytomX Therapeutics Inc. (CTMX) (IPO in October 2015: Biopharmaceutical company; antibody therapeutics, oncology)

Epizyme, Inc. (EPZM) (Biopharmaceutical company: therapeutics for patients with genetically defined cancers)

Geron Corporation (GERN) (Biopharmaceutical company: telomerase inhibitor in hematologic myeloid malignancies)

Halozyme Therapeutics, Inc. (HALO) (Oncology therapies that target the tumor microenvironment)

Hutchison China MediTech Limited (HCM) (IPO March 17, 2016: Biopharmaceutical company focused on immunological diseases and oncology in addition to consumer health products)

Lion Biotechnologies, Inc. (LBIO) (Immunotherapies based on tumor infiltrating lymphocytes)

Loxo Oncology, Inc. (LOXO) (Cancer therapies)

MacroGenics, Inc. (MGNX) (Biopharmaceutical company: monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases)

Merrimack Pharmaceuticals, Inc. (MACK) (Biopharmaceutical company: cancer)

Merus N.V. (MRUS) (IPO May 19, 2016, Netherlands: immuno-oncology company)

Momenta Pharmaceuticals, Inc. (MNTA) (Therapeutics for oncology and autoimmune indications)

Nantkwest Inc. (NK) (IPO in June 2015: Immunotherapy company: cancer)

NewLink Genetics Corporation (NLNK) (Biopharmaceutical company: immunotherapy products, pancreatic cancer)

NovoCure Ltd. (NVCR) (IPO in October 2015, oncology company: treatment of solid tumor cancers)

OncoMed Pharmaceuticals, Inc. (OMED) (Biopharmaceutical company: antibody therapeutics targeting cancer stem cells)

Protagonist Therapeutics, Inc. (PTGX) (IPO August 11, 2016: biopharmaceutical company with a platform focused on discovering and developing peptide-based new chemical entities)

Puma Biotechnology Inc. (PBYI) (Biopharmaceutical company: products for the treatment of various forms of cancer)

Sorrento Therapeutics, Inc. (SRNE) (Oncology company: treatments for cancer and associated pain)

Spectrum Pharmaceuticals, Inc. (SPPI) (Hematology, oncology)

Xbiotech Inc. (XBIT) (IPO in April 2015, biopharmaceutical company: cancer antibodies)

Ziopharm Oncology Inc. (ZIOP)  (Biopharmaceutical company: cell-based therapies for the treatment of cancer)

Central Nervous System

Intra-Cellular Therapies Inc. (ITCI) (Biopharmaceutical company: drugs for the treatment of diseases and disorders of the Central Nervous System)

Minerva Neurosciences, Inc. (NERV) (Biopharmaceutical company: central nervous system diseases)

Omeros Corporation (OMER) (Biopharmaceutical company: small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system)

Sage Therapeutics, Inc. (SAGE) (Biopharmaceutical company: rare central nervous system disorders)


Retrophin, Inc. (RTRX) (Biopharmaceutical company: catastrophic diseases affecting children)


Axovant Sciences Ltd. (AXON) (Therapeutics designed to treat dementia)


Lexicon Pharmaceuticals, Inc. (LXRX) (Biopharmaceutical company: treatment of type 1 and type 2 diabetes, treatment of carcinoid syndrome)

MannKind Corporation (MNKD) (Biopharmaceutical company: therapeutic products for diseases which include diabetes)


Otonomy, Inc. (OTIC) (Biopharmaceutical company: therapeutics for the treatment of diseases and disorders of the ear)

Endocrine Disorders

Versartis, Inc. (VSAR) (Biopharmaceutical company: treatment of endocrine disorders)


Ardelyx, Inc. (ARDX) (Molecule therapeutics: gastrointestinal)

Seres Therapeutics Inc. (MCRB) (IPO in June 2015: microbiome therapeutics platform)

Synergy Pharmaceuticals, Inc. (SGYP) (Biopharmaceutical company: therapies for the treatment of gastrointestinal diseases and disorders)

Gene Control

Syros Pharmaceuticals, Inc. (SYRS) (IPO June 30, 2016: Biopharmaceutical company, gene control medicines)

Gene Editing

CRISPR Therapeutics (CRSP) (IPO October 19, 2016: Switzerland, gene editing)

Intellia Therapeutics, Inc. (NTLA) (IPO May 6, 2016: gene editing company)

Gene Therapies

Regenxbio Inc. (RGNX) (IPO in September 2015: In vivo gene therapy products designed to treat various diseases)

Spark Therapeutics, Inc. (ONCE) (Gene therapies: treatments for debilitating genetic diseases)

Voyager Therapeutics, Inc. (VYGR) (IPO in November 2015: clinical stage gene therapy company: central nervous system)


ANI Pharmaceuticals, Inc. (ANIP) (Branded and generic prescription pharmaceuticals)

Growth Hormone Deficiency

Ascendis Pharma (ASND) (IPO in January 2015: Denmark, biopharmaceutical company: growth hormone deficiency, pulmonary arterial hypertension)


Amarin Corporation Plc. (AMRN) (Ireland, biopharmaceutical company: cardiovascular health)

MyoKardia Inc. (MYOK) (IPO in October 2015: Biopharmaceutical company; therapies for serious and neglected rare cardiovascular diseases)

Immune System

Ra Pharmaceuticals, Inc. (RARX) (Complement-mediated diseases)

Selecta Biosciences, Inc. (SELB) (IPO June 22, 2016: clinical-stage biopharmaceutical company focused on products designed to modulate the immune system)


Agenus Inc. (AGEN) (Immunology: cancer, infectious diseases)

Infectious Diseases

BioCryst Pharmaceuticals, Inc. (BCRX) (Infectious and inflammatory diseases)

Novavax, Inc. (NVAX) (Vaccine company; products to prevent infectious diseases)

Paratek Pharmaceuticals, Inc. (PRTK) (Antibiotics)

Sinovac Biotech, Ltd. (SVA) (China: Biopharmaceutical company: vaccines that protect against human infectious diseases)


Akebia Therapeutics, Inc. (AKBA) (Biopharmaceutical company: anemia secondary to chronic kidney disease)

Keryx Biopharmaceuticals, Inc. (KERX) (Biopharmaceutical company: renal disease)

Rockwell Medical, Inc. (RMTI) (Biopharmaceutical company: end-stage renal disease and chronic kidney disease)


Enanta Pharmaceuticals, Inc. (ENTA) (Small molecule drugs for viral infections and liver diseases)


Forward Pharma (FWP) (Denmark: immunomodulatory compound dimethyl fumarate and derivatives used to treat immune disorders including multiple sclerosis and psoriasis)


Cytokinetics, Incorporated (CYTK) (Biopharmaceutical company: debilitating diseases in which muscle performance is compromised and/or declining)


Acorda Therapeutics, Inc. (ACOR) (Biopharmaceutical company: neurological disorders)

Avexis Inc. (AVXS) (IPO February 11, 2016: Gene therapy company with a focus on rare neurological genetic diseases)

Edge Therapeutics Inc. (EDGE) (IPO in October 2015: Neurological conditions)

Vanda Pharmaceuticals Inc. (VNDA) (Biopharmaceutical company: atopic dermatitis, Non-24-Hour Disorder, schizophrenia)


Alder BioPharmaceuticals, Inc. (ALDR) (Biopharmaceutical company: migraine, autoimmune diseases and inflammatory diseases)

CoLucid Pharmaceuticals, Inc. (CLCD) (Biopharmaceutical company: treatment of migraines)

Rare Diseases

Acceleron Pharma Inc. (XLRN) (Cancer and orphan diseases)

Amicus Therapeutics, Inc. (FOLD) (Biopharmaceutical company: lysosomal storage diseases)

Audentes Therapeutics, Inc. (BOLD) (IPO July 20, 2016: biotech company focused on therapy treatments for rare diseases)

Corbus Pharmaceuticals Holdings, Inc. (CRBP) (Biopharmaceutical company: rare, life-threatening, inflammatory diseases)

Sarepta Therapeutics, Inc. (SRPT) (Biopharmaceutical company: RNA-based therapeutics; rare and infectious diseases)

Regenerative Medicine

BioTime, Inc. (BTX) (Regenerative medicine to patients with serious diseases and degenerative conditions)

Mesoblast Ltd. (MESO) (IPO in November 2015, Australia: regenerative medicine company; areas of focus include inflammation, cardiovascular disease and back pain)


Innoviva, Inc. (INVA) (Royalty: bio-pharmaceuticals, respiratory assets)

Insmed, Inc. (INSM) (Biopharmaceutical company: lung disease and pulmonary arterial hypertension)

Proteostasis Therapeutics, Inc. (PTI) (IPO February 11, 2016: Biopharmaceutical company with an initial focus on cystic fibrosis)


Dermira, Inc. (DERM) (Biopharmaceutical company: products for dermatologists and their patients)

Weight Management

Arena Pharmaceuticals, Inc. (ARNA) (Biopharmaceutical company: drugs that target G protein-coupled receptors; weight management)

Women’s Health

Myovant Sciences Ltd. (MYOV) (IPO October 27, 2016: biopharmaceutical company, women’s health and other endocrine-related disorders)